The risk factors associated with the greatest increased odds of anti-TNFα therapy were as follows: initial systemic disorder associated with uveitis [OR = 11.22 (1.37–91.85), p = 0.0241], family history of autoimmune diseases [OR = 9.43 (2.27–39.15), p = 0.0020], uveitis diagnosis before the age of 6 [OR = 4.05 (1.16–14.13), p = 0.0284], eye surgery [OR = 26.22 (2.63–261.77), p = 0.0054], and ocular complications at the first slit lamp exam [OR = 67.11 (3.78–1191.69), p = 0.0042]. The gene discussed is TNF; the disease is autoimmune disease.